Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keio University

www.keio.ac.jp

Latest From Keio University

BiomX Wants To Reverse The Focus Of Microbiome Therapy

Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.

StartUps and SMEs Platform Technologies

Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations

Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.

Deals Commercial

Acucela Inc.

Acucela is developing oral compounds that can possibly slow or stop vision loss caused by dry age-related macular degeneration. Its lead candidate is a small-molecule inhibitor of an enzyme called RPE65, known to be involved in the build-up of A2E, a toxic vitamin A by-product that is implicated in AMD.
BioPharmaceutical

California Stem Cell Inc.

California Stem Cell Inc.'s founder, Hans S. Keirstead, PhD, is well known in stem cell circles as the developer of processes that can produce extremely pure cell lines from human embryonic stem cells. As such, the start-up is uniquely situated. Not only does it produce over 95% pure populations of several cell types for use in research, but the firm also has proprietary reagents it sells to pharma and biotech firms. And it is building its own therapeutic pipeline: CSC is poised to file an IND for an hESC-derived therapy to treat type 1 infantile spinal muscular atrophy, the largest genetic killer of children under the age of two.
BioPharmaceutical
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register